• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis.通过从非酒精性脂肪性肝炎和胆汁淤积症推断来探索酒精性肝炎的新治疗模式。
J Hepatol. 2018 Aug;69(2):275-277. doi: 10.1016/j.jhep.2018.05.012. Epub 2018 May 21.
2
Reply to: "Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?
J Hepatol. 2018 Dec;69(6):1400-1401. doi: 10.1016/j.jhep.2018.09.017. Epub 2018 Oct 6.
3
Finding fibroblast growth factor 19 during cholestasis: Does x mark the spot?
J Hepatol. 2018 Dec;69(6):1399-1400. doi: 10.1016/j.jhep.2018.09.008. Epub 2018 Oct 4.
4
The effect of fibroblast growth factor 15 deficiency on the development of high fat diet induced non-alcoholic steatohepatitis.成纤维细胞生长因子15缺乏对高脂饮食诱导的非酒精性脂肪性肝炎发展的影响。
Toxicol Appl Pharmacol. 2017 Sep 1;330:1-8. doi: 10.1016/j.taap.2017.06.023. Epub 2017 Jul 1.
5
Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的胆汁酸与肠道菌群失调
PLoS One. 2016 May 20;11(5):e0151829. doi: 10.1371/journal.pone.0151829. eCollection 2016.
6
Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD.非酒精性脂肪性肝病患儿肝法尼醇 X 受体蛋白水平与循环成纤维细胞生长因子 19 浓度。
Liver Int. 2018 Feb;38(2):342-349. doi: 10.1111/liv.13531. Epub 2017 Aug 18.
7
An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors.一种雌激素受体β选择性激动剂通过调节胆汁酸和外源性物质受体在临床前模型中抑制非酒精性脂肪性肝炎。
Exp Biol Med (Maywood). 2017 Mar;242(6):606-616. doi: 10.1177/1535370216688569. Epub 2017 Jan 16.
8
Farnesoid X receptor modulators 2014-present: a patent review.法尼醇 X 受体调节剂 2014 年至今：专利研究综述。
Expert Opin Ther Pat. 2018 May;28(5):351-364. doi: 10.1080/13543776.2018.1459569. Epub 2018 Apr 13.
9
Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis.酒精性肝炎与非酒精性脂肪性肝炎：一些与肿瘤发生相关的蛋白表达水平。
Exp Mol Pathol. 2018 Feb;104(1):45-49. doi: 10.1016/j.yexmp.2017.12.007. Epub 2018 Jan 4.
10
Expression of proteins upregulated in hepatocellular carcinoma in patients with alcoholic hepatitis (AH) compared to non-alcoholic steatohepatitis (NASH): An immunohistochemical analysis of candidate proteins.与非酒精性脂肪性肝炎（NASH）相比，在酒精性肝炎（AH）患者中上调的肝细胞癌蛋白的表达：候选蛋白的免疫组织化学分析。
Exp Mol Pathol. 2018 Apr;104(2):125-129. doi: 10.1016/j.yexmp.2018.02.001. Epub 2018 Feb 6.

引用本文的文献

1
Current and emerging therapies for alcohol-associated hepatitis.酒精性肝炎的现有及新兴疗法
Liver Res. 2023 Mar 15;7(1):35-46. doi: 10.1016/j.livres.2023.03.002. eCollection 2023 Mar.
2
Alcohol-related liver disease (ALD): current perspectives on pathogenesis, therapeutic strategies, and animal models.酒精性肝病（ALD）：关于发病机制、治疗策略及动物模型的当前观点
Front Pharmacol. 2024 Nov 28;15:1432480. doi: 10.3389/fphar.2024.1432480. eCollection 2024.
3
Advances in the management of alcohol-associated liver disease.酒精性肝病管理的进展
Gastroenterol Rep (Oxf). 2024 Nov 5;12:goae097. doi: 10.1093/gastro/goae097. eCollection 2024.
4
Unraveling the Complex Interplay between Epigenetics and Immunity in Alcohol-Associated Liver Disease: A Comprehensive .解析酒精相关性肝病中表观遗传学与免疫之间的复杂相互作用：全面综述
Int J Biol Sci. 2023 Sep 4;19(15):4811-4830. doi: 10.7150/ijbs.87975. eCollection 2023.
5
New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease.酒精性肝病中胆汁酸调控机制的新见解及治疗展望。
Cell Mol Life Sci. 2022 Aug 17;79(9):486. doi: 10.1007/s00018-022-04509-6.
6
Farnesoid X Receptor as Target for Therapies to Treat Cholestasis-Induced Liver Injury.法尼醇 X 受体作为治疗胆汁淤积性肝损伤的靶点。
Cells. 2021 Jul 21;10(8):1846. doi: 10.3390/cells10081846.
7
Emerging medical therapies for severe alcoholic hepatitis.治疗严重酒精性肝炎的新兴医学疗法。
Clin Mol Hepatol. 2020 Oct;26(4):686-696. doi: 10.3350/cmh.2020.0145. Epub 2020 Sep 28.
8
Highlights From the AASLD/EASL ALD Endpoints Conference 2019.2019年美国肝病研究学会/欧洲肝脏研究学会酒精性肝病终点会议亮点
Clin Liver Dis (Hoboken). 2020 Jun 30;15(6):215-218. doi: 10.1002/cld.927. eCollection 2020 Jun.
9
Severe alcoholic hepatitis: current perspectives.严重酒精性肝炎：当前观点
Hepat Med. 2019 Aug 8;11:97-108. doi: 10.2147/HMER.S197933. eCollection 2019.

本文引用的文献

1
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.NGM282 治疗非酒精性脂肪性肝炎：一项多中心、随机、双盲、安慰剂对照的 2 期临床试验。
Lancet. 2018 Mar 24;391(10126):1174-1185. doi: 10.1016/S0140-6736(18)30474-4. Epub 2018 Mar 5.
2
Modulating bile acid pathways and TGR5 receptors for treating liver and GI diseases.调节胆汁酸途径和 TGR5 受体治疗肝脏和胃肠道疾病。
Curr Opin Pharmacol. 2017 Dec;37:80-86. doi: 10.1016/j.coph.2017.09.008. Epub 2017 Nov 5.
3
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.ASK1 抑制剂 selonsertib 治疗非酒精性脂肪性肝炎患者的随机、2 期临床试验。
Hepatology. 2018 Feb;67(2):549-559. doi: 10.1002/hep.29514. Epub 2017 Dec 26.
4
Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.酒精性脂肪性肝炎和非酒精性脂肪性肝炎的治疗机会：从发病机制的异同中寻找突破。
JCI Insight. 2017 Sep 7;2(17). doi: 10.1172/jci.insight.95354.
5
A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.一项关于西尼利尤单抗治疗伴有纤维化的非酒精性脂肪性肝炎的随机、安慰剂对照试验。
Hepatology. 2018 May;67(5):1754-1767. doi: 10.1002/hep.29477. Epub 2018 Jan 29.
6
The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.非酒精性脂肪性肝炎的存在和严重程度与循环胆汁酸的特定变化有关。
Hepatology. 2018 Feb;67(2):534-548. doi: 10.1002/hep.29359. Epub 2017 Dec 23.
7
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.奥贝胆酸治疗原发性胆汁性胆管炎的安慰剂对照临床试验。
N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840.
8
Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.非酒精性脂肪性肝病中的胆汁酸与肠道菌群失调
PLoS One. 2016 May 20;11(5):e0151829. doi: 10.1371/journal.pone.0151829. eCollection 2016.
9
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.依洛前列素，一种过氧化物酶体增殖物激活受体-α和-δ激动剂，可在不加重肝纤维化的情况下诱导非酒精性脂肪性肝炎消退。
Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11.
10
Prednisolone or pentoxifylline for alcoholic hepatitis.泼尼松龙或己酮可可碱治疗酒精性肝炎。
N Engl J Med. 2015 Apr 23;372(17):1619-28. doi: 10.1056/NEJMoa1412278.

Exploring new treatment paradigms for alcoholic hepatitis by extrapolating from NASH and cholestasis.

作者信息

Peeraphatdit Thoetchai Bee, Simonetto Douglas A, Shah Vijay H

机构信息

Gastroenterology Research Unit, Mayo Clinic, 200 First Street, SW, Rochester, MN, USA.

Gastroenterology Research Unit, Mayo Clinic, 200 First Street, SW, Rochester, MN, USA.

出版信息

J Hepatol. 2018 Aug;69(2):275-277. doi: 10.1016/j.jhep.2018.05.012. Epub 2018 May 21.

DOI:10.1016/j.jhep.2018.05.012
PMID:29792896
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6258016/
Abstract
摘要